1Parul T, Prashant T, Luv K, et al. The role of nitric oxidein inflam- matory reactions [ J ]. FEMS Immunol Med Microbiol, 2007,51 ( 3 ) :443-452.
2Abramson S B. Osteoarthritis and nitric oxide [ J ]. Osteoarthritis Cartilage, 2008,16 : S15-20.
3Amin A R,Abramason. Pannocyte:distinctive cell found in rheu- matoid arthritis articular cartilage erosions [ J ]. Curr Opin Rheuma- tol, 1998,10 ( 3 ) :263-268.
4Johnston S A, Fox S M. Mechanisms of action anti-inflmmatory me- dications used for the treatment of osteoarthritis[ J].J Am Vet Med Assoc, 1997,210 ( 10 ) : 1486-1492.
5Kaur H, Halliwell B. Evidence for nitric nxide-mediated oxidative damage in chronic inflammation. Nitrotyrosine in serum and synovi- al fluid from rheumatoid patients[ J]. FEBS Lett, 1994,350:9-12.
6Blanco Caria F G. Gatabolic eventc in osteoarthritis cartilage[ J]. Osteoarthritis Cartilage, 1999,7 ( 3 ) :308-309.
7Studder R, Jaffurs D, Bobbins P D. Nitric oxide in osteoarthritis [ J ]. Osteoarthritis Cartilage, 1999,7 ( 4 ) : 377 -379.
8Salvatierra J, Escame G, Cantero J. Cartilage and serum levels of nitric oxide in patients with hip[ J]. Osteoarthritis J Rheumatol, 1999,26(9) :2015-2017.
9Grabowski P S, Raiston S H, Macpherson H. Nitric oxide produc- tion in cells derived from the human joint [ J ]. Br J Rheumatol, 1996,35:207-212.
10Pelletier J P. Pathological targets in OA therapy [ J]. Osteoarthritis Cartilage, 1999,7 ( 3 ) :308-309.
7Miyazaki T, Wada M, Kawahara H, et al. Dynamic load at baseline can predict radiographic disease progression in medial compartment knee osteoarthritis [ J ]. Ann Rheum Dis, 2002,61 (7) : 617-622.
8McCarty M F, Russell A L. Seed MP Sulfated glycosaminoglycans and glucosamine may synergize in promoting synovial hyaluronic acid synthesis [ J ]. Med Hypotheses, 2000,54 ( 5 ) : 798-802.
9Nishimoto S, Takagi M, Wakitani S, et al. Effect of chondroitin sulfate and hyaluronic acid on gene expression in a three-dimensional culture of chondrocytes [ J ]. J Biosci Bioeng, 2005,100 ( 1 ) : 123-126.
10Chikanza I, Fernandes L. Novel strategies for the treatment of osteroarthritis [ J ]. Expert Opin Invest Drugs, 2000,9 (7) : 1499-1503.
2Boswell MY, Shah RV, Everett CR, et al.lnterventional techniques in the management of chronic spinal pain:Evidencebased practice guidelines.Pain Physician.2005;8:1-47.
3Offierski CM, MacNab I.Hip-spine syndrome.Spine. 1983; 8(3):316-321.
4Katz JN, Lipson S J, Larson MG, et al. The outcome of decompressive laminectomy for degenerative lumbar stenosis, J Bone Joint Surg Am.1991 ;73:809-816.
5Dreyer S J, Dreyfuss PH.Low back pain and the zygapophysial(facet) joints. Arch Phys Med Rehabil. 1996:77:290-300.
6Polkowski GG, Clohisy JC. Hip Biomechanics.Sports M& Arthroscopy R.2010;6(18):56-62.
7Femaodes JC, MarteI-Pelletier J, Pelletier JP.The role of eytokines in osteoarthritis pathophysiology. Biorheology. 2002;39(1-2):237-246.
8Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of Creactive protein with adiponectin in blood stream and adipose tissue.Circulation.2003; 107:671-674.
9Chert TH, Chen L, Hsieh MS, et al. Evidence for a protective role for adiponectin in osteoarthritis. Biochim Biophys Acta. 2006;1762(8):711-718.
10Honsawek S, Chayanupatkul M..Correlation of Plasma and Synovial Fluid Adiponectin with Knee Osteoarthritis Severity. Archives of Medical Research.2010;42:593-598.
